.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,958,459

« Back to Dashboard

Details for Patent: 5,958,459

Title: Opioid formulations having extended controlled released
Abstract:Solid controlled-release oral dosage forms comprising a therapeutically effective amount of an opioid analgesic or a salt thereof which provide an extended duration of pain relief of about 24 hours, have a dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of 100 rpm in 900 ml aqueous buffer at 37.degree. C. from about 12.5% to about 42.5% (by weight) active agent released after 1 hour, from about 25% to about 55% (by weight) active agent released after 2 hours, from about 45% to about 75% (by weight) opioid analgesic released after 4 hours and greater than about 60% (by weight) opioid analgesic released after 8 hours, the in-vitro release rate being substantially independent of pH and chosen such that the peak plasma level of active agent obtained in-vivo between about 2 and about 8 hours after administration of the dosage form.
Inventor(s): Chasin; Mark (Manalapan, NJ), Oshlack; Benjamin (New York, NY), Pedi, Jr.; Frank (Yorktown Heights, NY)
Assignee: Purdue Pharma L.P. (Norwalk, CT)
Filing Date:Nov 27, 1995
Application Number:08/561,829
Claims:1. A solid controlled release oral dosage form, the dosage form consisting of a plurality of inert pharmaceutical beads coated with an analgesically effective amount of an opioid analgesic or a mixture of opioid analgesics or a salt thereof said inert pharmaceutical beads overcoated with a controlled-release coating, wherein the dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of U.S. Pharmacopeia XXII (1990) at 100 rpm at 900 ml aqueous buffer at 1.6 and 7.2 pH and 37.degree. C. is from about 16.8% to about 42.5% (by wt) opioid released after 1 hour, from about 25% to about 65% (by wt) opioid released after 2 hours, from about 45% to about 85% (by wt) opioid released after 4 hours and greater than about 60% (by wt) opioid released after 8 hours, the in-vitro release rate being substantially independent of pH in that a difference at any given time between an amount of opioid released at one pH and an amount released at any other pH, when measured in-vitro using the USP Paddle Method of U.S. Pharmacopeia XXII (1990) at 100 rpm in 900 ml aqueous buffer, is no greater than 10%, the in-vitro release rate being chosen such that the peak plasma level of said opioid obtained in-vivo occurs from about 2 to about 8 hours after administration of the dosage form; said dosage form providing an extended duration of therapeutic effect of about 24 hours.

2. The dosage form of claim 1, wherein said opioid analgesic is selected from the group consisting of hydromorphone, oxycodone, morphine, levorphanol, methadone, meperidine, heroin, dihydrocodeine, codeine, dihydromorphine, buprenorphine, salts thereof, and mixtures thereof.

3. A dosage form according to claim 1 wherein said opioid analgesic comprises hydromorphone.

4. A dosage form according to claim 1 wherein said opioid analgesic comprises morphine.

5. A dosage form according to claim 1 wherein said opioid analgesic comprises oxycodone.

6. A dosage form according to claim 1, wherein said controlled release coating comprises a hydrophobic polymer selected from the group consisting of (i) a plasticized acrylic polymer; (ii) plasticized ethylcellulose, or (iii) a mixture of (i) and (ii).

7. The dosage form of claim 6, wherein said controlled release coating comprises a hydrophobic polymer which is applied to said inert pharmaceutical beads as an aqueous dispersion.

8. A dosage form according to claim 1, wherein said opioid analgesic consists of from about 4 mg to about 64 mg hydromorphone.

9. A dosage form according to claim 1, wherein said opioid analgesic consists of from about 15 mg to about 800 mg morphine.

10. A dosage form according to claim 1, wherein said opioid analgesic consists of from about 10 mg to about 400 mg oxycodone.

11. A dosage form according to claim 1 which provides a peak plasma level of said opioid in-vivo from about 4 to about 6 hours after administration.

12. The dosage form according to claim 1 in which the controlled release coating comprises a release-modifying agent.

13. A dosage form according to claim 1, wherein said controlled release coating comprises a copolymer of acrylic and methacrylic acid.

14. A dosage form according to claim 1, wherein said controlled release coating comprises a material selected from the group consisting of methyl methacrylate copolymer, ethoxyethyl methacrylate, cyanoethyl methacrylate, poly(acrylic acid), poly(methacrylic acid), methacrylic acid alkylamide copolymer, poly(methyl methacrylate), polymethacrylate, poly(methyl methacrylate) copolymer, polyacrylamide, aminoalkyl methacrylate copolymer, poly(methacrylic acid anhydride), and glycidyl methacrylate copolymer.

15. A dosage form according to claim 1, wherein said controlled release coating comprises an alkylcellulose.

16. A dosage form according to claim 1, wherein said controlled release coating comprises one or more ammonio methacrylate copolymers.

17. A dosage form according to claim 6, wherein said opioid analgesic is selected from the group consisting of hydromorphone, oxycodone, levorphanol, methadone, meperidine, heroin, dihydrocodeine, codeine, dihydromorphine, buprenorphine, hydrocodone, mixed mu-agonists/antagonists, mu-agonist/antagonist combinations, salts thereof, and mixtures of any of the foregoing.

18. A dosage form according to claim 1, wherein the dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of U.S. Pharmacopeia XXII (1990) at 100 rpm at 900 ml aqueous buffer at 1.6 and 7.2 pH and 37.degree. C. is about 31.1% (by wt) opioid released after 1 hour, about 37% (by wt) opioid released after 2 hours, about 51.5% (by wt) opioid released after 4 hours and greater than about 60% (by wt) opioid released after 8 hours.

19. A dosage form according to claim 6, wherein the dissolution rate in-vitro of the dosage form, when measured by the USP Paddle Method of U.S. Pharmacopeia XXII (1990) at 100 rpm at 900 ml aqueous buffer (pH between 1.6 and 7.2) at 37.degree. C. is about 31.1% (by wt) opioid released after 1 hour, about 37% (by wt) opioid released after 2 hours, about 51.5% (by wt) opioid released after 4 hours and greater than about 60% (by wt) opioid released after 8 hours.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc